Equities research analysts at StockNews.com assumed coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Get Free Report) in a note issued to investors on Tuesday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.
Akari Therapeutics Price Performance
Shares of NASDAQ:AKTX opened at $1.19 on Tuesday. Akari Therapeutics has a 12 month low of $1.08 and a 12 month high of $5.50. The stock’s 50 day moving average price is $1.94 and its 200 day moving average price is $2.72.
Institutional Inflows and Outflows
Hedge funds have recently added to or reduced their stakes in the business. Omnia Family Wealth LLC grew its position in Akari Therapeutics by 48.2% during the 4th quarter. Omnia Family Wealth LLC now owns 87,628 shares of the biopharmaceutical company’s stock worth $273,000 after purchasing an additional 28,511 shares in the last quarter. Cerity Partners LLC acquired a new stake in shares of Akari Therapeutics during the 2nd quarter valued at $55,000. Sabby Management LLC boosted its stake in shares of Akari Therapeutics by 116.5% during the 1st quarter. Sabby Management LLC now owns 7,941,867 shares of the biopharmaceutical company’s stock valued at $1,443,000 after buying an additional 4,273,528 shares during the period. Renaissance Technologies LLC lifted its stake in shares of Akari Therapeutics by 411.4% in the 1st quarter. Renaissance Technologies LLC now owns 283,550 shares of the biopharmaceutical company’s stock valued at $52,000 after purchasing an additional 228,100 shares during the last quarter. Finally, LPL Financial LLC acquired a new stake in shares of Akari Therapeutics in the 2nd quarter valued at $83,000. Institutional investors and hedge funds own 5.06% of the company’s stock.
Akari Therapeutics Company Profile
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.
Further Reading
- Five stocks we like better than Akari Therapeutics
- What is the Dow Jones Industrial Average (DJIA)?
- United Airlines Soars on Earnings Beat
- High Dividend REITs: Are They an Ideal Way to Diversify?
- J.B. Hunt Hits the Skids: Lower Prices to Come
- What is the S&P 500 and How It is Distinct from Other Indexes
- Predicting a Bear Market: 7 Signs and Why it’s Tough to Do
Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.